Specialty Pharmacy

Scott Gottlieb has served as the FDA Deputy Commissioner under President George W. Bush, a senior advisor to the FDA commissioner, and as FDA Director of Medical Policy Development.

Avelumab (Bavenico) approved for advanced or metastatic urothelial carcinoma.

Substantial proportion of patients with ulcerative colitis or Crohn’s disease achieved mucosal healing with vedolizumab.

MedChew Rx is a cannabidiol that treats pain and spasticity associated with multiple sclerosis.

Kisqali Femara Co-Pack only requires 1 co-payment.

Top news of the day from across the health care landscape.

A malaria protein combined with an anti-cancer drug shows promise against chemotherapy-resistant bladder cancer.

Data show communication failure accounted for 71% of serious or life-threatening errors related to medication errors.

The current outlook for biosimilar manufacturers shows significant promise.

Cellular mechanism may present treatment target for multiple sclerosis.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses the largest challenges currently facing independent specialty pharmacies.

Regular low-dose aspirin use associated with a lower risk of breast cancer.

Top news of the day from across the health care landscape.

Suppressing MAFK pathway in tumor cells may slow spread of aggressive breast cancer.

Active compounds in chili peppers and cannabinoids help calm the gut.

Top articles of the week on Specialty Pharmacy Times.

Study provides visualization of different conformations of transporter in motion that may lead to more effective anticancer and antiviral drugs.

Patients who received kidney transplants from donors infected with hepatitis C virus were cured after antiviral drug therapy.

The American Health Care Act is designed to repeal and replace parts of the Affordable Care Act.

Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.

Opioid epidemic fuels hepatitis C transmission.

FDA authorizes an omalizumab (Xolair) biosimilar to commence clinical trials.

GBR 310 is a recombinant DNA-derived monoclonal antibody for the treatment of allergic asthma and chronic idiopathic urticaria.

Findings may lead to the development of a noninvasive clinical diagnostic test.

The risk of comorbid chronic obstructive pulmonary disorder in patients infected with HIV may be underestimated.

Eric Peacock, CEO of MyHealthTeams, discusses effective treatment of patients with chronic conditions.

Specialty pharmacy is the fastest growing segment thanks to drug innovation that is driving health care costs.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.